FY2026 EPS Estimates for Roche Reduced by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Investment analysts at Erste Group Bank reduced their FY2026 earnings per share estimates for shares of Roche in a research note issued on Tuesday, September 8th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $3.14 for the year, down from their previous estimate of $3.16. The consensus estimate for Roche’s current full-year earnings is $3.06 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.41 EPS.

Several other research firms have also recently commented on RHHBY. Royal Bank Of Canada started coverage on shares of Roche in a research report on Tuesday, September 8th. They issued an “outperform” rating for the company. Zacks Research raised shares of Roche from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. HSBC reaffirmed a “hold” rating on shares of Roche in a research report on Thursday, September 10th. Finally, Morgan Stanley raised Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price for the company in a research report on Friday, August 7th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

Roche Price Performance

RHHBY opened at $54.95 on Monday. The stock’s 50 day moving average price is $54.55 and its 200-day moving average price is $52.50. Roche has a 52-week low of $39.50 and a 52-week high of $60.85. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12.

Institutional Trading of Roche

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Renasant Bank bought a new position in Roche during the 2nd quarter valued at approximately $210,000. North Star Asset Management Inc. bought a new stake in Roche in the second quarter worth $1,351,000. Puzo Michael J purchased a new stake in shares of Roche in the second quarter worth $1,229,000. Fulton Bank N.A. grew its stake in shares of Roche by 5.1% in the second quarter. Fulton Bank N.A. now owns 11,572 shares of the company’s stock worth $597,000 after acquiring an additional 559 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Roche by 14.3% during the second quarter. GAMMA Investing LLC now owns 29,015 shares of the company’s stock valued at $1,490,000 after acquiring an additional 3,625 shares in the last quarter.

About Roche

Roche Holding AG is a Switzerland-based healthcare company that develops and provides pharmaceutical products and diagnostic solutions. Founded in 1896 and headquartered in Basel, Roche operates through two complementary divisions: Pharmaceuticals and Diagnostics.

The Pharmaceuticals division focuses on medicines for oncology, immunology, neuroscience, ophthalmology, hematology and other therapeutic areas. Its portfolio includes treatments such as Ocrevus, Hemlibra, Perjeta, Tecentriq and Vabysmo.